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Background. In resource-constrained settings, many people with HIV (PWH) are treated for tuberculosis (TB) without bacte-
riologic testing. Their mortality compared with those with bacteriologic testing is uncertain.
Methods. We conducted an observational cohort study among PWH ≥15 years of age initiating TB treatment at sites affiliated 
with 4 International epidemiology Databases to Evaluate AIDS consortium regions from 2012 to 2014: Caribbean, Central and South 
America, and Central, East, and West Africa. The exposure of interest was the TB bacteriologic test status at TB treatment initiation: 
positive, negative, or no test result. The hazard of death in the 12 months after TB treatment initiation was estimated using a Cox 
proportional hazard model. Missing covariate values were multiply imputed.
Results. In 2091 PWH, median age 36 years, 53% had CD4 counts ≤200 cells/mm3, and 52% were on antiretroviral therapy 
(ART) at TB treatment initiation. The adjusted hazard of death was higher in patients with no test compared with those with posi-
tive test results (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.08–2.26). The hazard of death was also higher among those 
with negative compared with positive tests but was not statistically significant (HR, 1.28; 95% CI, 0.91–1.81). Being on ART, having 
a higher CD4 count, and tertiary facility level were associated with a lower hazard for death.
Conclusions. There was some evidence that PWH treated for TB with no bacteriologic test results were at higher risk of death 
than those with positive tests. Research is needed to understand the causes of death in PWH treated for TB without bacteriologic 
testing.
Keywords. adults; epidemiology; HIV; mortality; tuberculosis.
Diagnosing tuberculosis (TB) in people with HIV (PWH) re-
mains a challenge in resource-limited settings. In 2017, only 
56% of the 5.5 million global pulmonary TB cases reported to 
the World Health Organization (WHO) were bacteriologically 
confirmed (ie, positive for smear microscopy, culture, or nu-
cleic acid amplification test [NAAT]) [1]. In autopsy studies of 
TB in HIV-related deaths, TB was prevalent in 37% of deaths 
but was not diagnosed by the time of death in half of cases [2]. 
The rollout of NAATs such as the Xpert MTB/RIF (Cepheid, 
Sunnyvale, CA, USA), which are more sensitive and specific 
than smear microscopy, has helped close this gap [3]. However, 
limited impact on mortality has been observed with the use of 
Xpert MTB/RIF, in part due to high baseline rates of empiric TB 
treatment in high–TB burden settings [3–5]. Additionally, de-
spite the higher sensitivity of Xpert compared with direct smear 
microscopy and increasing use of Xpert globally, there has not 
been a general increase in the proportion of notified pulmo-
nary TB cases that are bacteriologically confirmed in low- and 
middle-income countries, including in the 30 high–TB burden 
countries [6]. A better understanding of mortality among PWH 
treated for TB in the setting of varying TB test results, or the 
absence of TB testing, is needed to inform the management of 
PWH treated for TB in resource-limited settings.
Acquiring a TB bacteriologic diagnosis in resource-limited 
settings can be challenging for multiple reasons. Despite in-
creases in TB bacteriologic test coverage in sub-Saharan Africa, 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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smear microscopy and culture are estimated to be available at 
only 1.4 and 0.7 laboratories per 100  000 population, respec-
tively [7, 8]. Many labs suffer from weak supply systems, out-
dated equipment, poor quality control, and insufficient staffing 
[7, 9–11]. Smear microscopy for acid-fast bacilli (AFB) is often 
the only TB test available but is poorly sensitive in PWH, with 
30%–60% of pulmonary TB cases reported to be smear nega-
tive [12–14]. Clinicians may not order TB bacteriologic testing 
among PWH due to lack of knowledge about TB (or, conversely, 
knowledge of smear microscopy’s limitations), or in cases of sus-
pected extrapulmonary TB for which invasive tissue sampling 
cannot be performed [5, 9, 15, 16]. Patients may not be able to 
produce a sputum sample for bacteriologic testing or access TB 
testing sites due to the distance or cost of transport [9, 17, 18].
Empiric TB treatment in PWH, either because a bacteriologic 
test was negative or no test was performed, is thus common in 
resource-limited settings [4, 5, 14, 19, 20]. However, mortality 
in the absence of TB bacteriologic testing is not well defined 
[21–24]. The objective of this study was to describe the char-
acteristics and risk of death among PWH treated for TB in the 
context of positive, negative, or no TB bacteriologic test results.
METHODS
Setting and Patient Population
This observational cohort study utilized data collected from PWH 
enrolled in HIV care programs affiliated with 4 participating re-
gions of the International epidemiology Databases to Evaluate 
AIDS (IeDEA) consortium: Caribbean, Central and South America 
(CCASAnet) and Central, East, and West Africa [25]. IeDEA is a 
National Institutes of Health (NIH)–funded consortium that pools 
and harmonizes patient data collected in the context of routine care 
[26]. All participating facilities provided standard-of-care HIV and 
TB treatment services per their respective national guidelines. The 
study population included all PWH ≥15 years of age who initiated 
TB treatment between January 2012 and December 2014. Patients 
were excluded if an alternative diagnosis was established and TB 
treatment was stopped. Recurrent TB cases within the study period 
were excluded (n = 41), so a patient could not contribute >1 TB 
case. Patients receiving a drug-resistant TB treatment regimen were 
also excluded, defined by WHO criteria as any injectable agent (ex-
cept streptomycin), fluoroquinolones, or oral bacteriostatic agent 
[27]. Patients with these characteristics were excluded in order to 
reduce the potential for confounding, given associations of these 
characteristics with adverse treatment outcomes and mortality in 
other studies [21, 28]. The reporting of this study conforms to the 
STROBE statement (Supplementary Table 1) [29].
Ethics Statement
Independent Ethics Committee or Institutional Review 
Board approval for this study was obtained by each of 
the local IeDEA sites as well as from Indiana University 
(Supplementary Table 2).
Data Management
TB cases were identified through review of local TB registries by 
site staff. An electronic case report form developed in Research 
Electronic Data Capture in English and French was used to collect 
medical record data [30]. Data entry into case report forms was 
performed by local IeDEA investigators. Patient-level HIV data 
were obtained from the IeDEA regional HIV care and treatment 
data repositories for patients with completed case report forms. 
Site-level data were obtained from surveys of antiretroviral therapy 
(ART) sites participating in IeDEA conducted between March 1 
and July 1, 2012 [31, 32]. Routine audits were performed to ensure 
data quality. Regional IeDEA data were transferred to the IeDEA-
East Africa Regional Data Center, where they were merged and ad-
ditional data quality assessments undertaken before analysis.
Study Definitions
Adult patients were defined as patients who were ≥15  years of 
age, consistent with WHO and other national and regional TB 
programs [33, 34]. The primary exposure of interest was the TB 
bacteriologic test status at TB treatment initiation: The positive 
test group included patients with ≥1 positive result including acid 
fast bacilli (AFB) smear, culture, or NAAT (Xpert MTB/RIF); the 
negative test group included patients for whom 1 or more of these 
bacteriologic tests were performed and none were positive; the no 
test group includes patients for whom no bacteriologic test was 
performed or results reported [35]. Patient-level variables at TB 
treatment initiation included age, sex, body mass index (BMI), 
ART status at TB treatment initiation, CD4 count (nearest value 
within 180 days before or 30 days after TB treatment initiation), 
TB disease site, and type of bacteriologic TB test (smear, culture, 
NAAT). Data on lipoarabinomannan (LAM) testing, which was 
recommended by the WHO for routine use in PWH in 2015 and 
was not used routinely at the time of the study, were not collected 
[36]. Specimen type (eg, respiratory vs nonrespiratory) was also 
not available. TB disease site was categorized into pulmonary 
and extrapulmonary according to WHO and Centers for Disease 
Control and Prevention definitions [33, 35, 37].
Site-level variables included IeDEA region, setting (urban, 
peri-urban), facility level (secondary [ie, district or provincial] vs 
tertiary [ie, regional or referral]), availability of specialized clinic/
ward with dedicated staff for TB patients, physical proximity of 
HIV/TB clinical services, and the nature of active screening for 
TB performed for all PWH at enrollment. Site-level variables were 
applied to each patient as individual characteristics. The main out-
come variable was death. Patients were followed from TB treat-
ment initiation until death or censoring within the 12  months 
following treatment initiation or June 1, 2015. Nondeath events 
within this period were considered censored events.
Data Analysis
Patient characteristics were summarized by each bacteriologic 
test group using frequencies and proportions for categorical 
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variables and medians and interquartile ranges for continuous 
variables. Differences between groups were assessed, as appro-
priate, using 1-way analysis of variance (ANOVA), the Pearson 
chi-square test, and the Fisher exact test. Survival for each 
group was estimated using the Kaplan-Meier method. The log-
rank test was used to test the equality of survival among the 
groups. The Cox proportional hazard model was used to esti-
mate the univariate and multivariable associations of covariates 
and the hazard of death. Independent variables included in this 
model were sex, age, BMI, CD4 count, ART status at TB treat-
ment initiation, TB disease site, IeDEA region, and facility level. 
These variables were selected a priori because of their associ-
ations with adverse TB treatment outcomes in prior studies [21, 
38–46].
The impact of missingness on the observed hazard asso-
ciations was assessed by refitting the models after imputing 
missing patient-level covariate values selected because of their 
independent associations with mortality in patients with TB/
HIV co-infection in prior studies [21, 42]. Missing values for 
CD4 count, BMI, and ART status at TB treatment initiation 
were multiply imputed using the fully conditional specification 
(FCS), where these covariates were assumed to be jointly dis-
tributed [47]. Imputation was performed 100 times following 
Rubin’s scheme [48, 49]. Imputation analysis was performed 
using the PROC MI procedure in SAS [50]. Analyses were per-
formed at the α = 0.05 level.
In a secondary analysis, the hazard of death was compared 
among those with any bacteriologic test (positive or negative) 
vs no test results using the Cox model. Owing to the aforemen-
tioned missing values and the covariate imbalance among those 
with and without test results, the analysis was performed se-
quentially as follows: 1) Missing values were imputed separately 
for those with and without a test result. 2) The propensity for 
having a bacteriologic test result was modeled using logistic 
regression while adjusting for the covariates considered in the 
primary analysis. 3) Propensity scores were used to construct 
stabilized inverse probability weights (IPWs) (Supplementary 
Table 3). 4) The hazard of death was modeled conditional on 
having a bacteriologic test while adjusting for stabilized IPWs. 
In step 4 of the sequence, the estimate of the log hazards ratio 
and its robust standard error estimate were obtained. Steps 1–4 
were repeated 100 times; resulting log-hazards ratio estimates 
and their standard errors were pooled using Rubin’s rules.
RESULTS
Patient- and Site-Level Characteristics
Among 2140 patients in the database, 49 were excluded for 
initiating TB treatment outside of the study period (n = 32) or 
before the TB diagnosis date (n = 1), for documentation errors 
(n = 13), or for receiving drug-resistant TB treatment regimens 
(n = 3). Thus, 2091 patients were included in the analysis. These 
patients received care in 12 countries in 4 participating IeDEA 
regions (Figure 1). The characteristics of patients stratified by 
TB bacteriologic test status are presented in Table  1. Overall, 
30% of patients had positive TB bacteriologic tests, 43% had 
negative tests, and 27% had no test results. Table 2 presents the 
patient distribution by site characteristics.
AFB smear was performed in 71% of patients (Supplementary 
Table 4). Culture and NAAT were performed in 8% and 3% 
of patients, respectively. Among patients with a positive test 
(whereby ≥1 test type may be performed for each patient), 90% 
had a positive AFB smear, 16% had a positive culture, and 6% 
had a positive NAAT. Among patients with results from >1 test 
type, 35% (27 of 78) with a negative AFB smear had a positive 
culture and 38% (14 of 37) with a negative smear had a positive 
NAAT (Supplementary Table 5).
A total of 243 (12%) deaths were reported: 64 (10%) deaths 
among those with a positive test, 99 (11%) among those with 
a negative test, and 80 (14%) in those with no test results 
(P = .099). Figure 2 shows the survival summary for the 2091 
patients. The corresponding log-rank test suggested evidence of 
a difference in survival among the 3 groups (P = .017).
Primary Analysis
Of the 2091 patients, 1258 (60%) were complete cases with 
respect to the analysis model (see Table  1 for proportion of 
missing values for each variable). Both the univariate and 
multivariable analyses were therefore restricted to these 1258 
subjects (Table 3). In the univariate and multivariable models, 
there was not sufficient evidence of a difference in hazards of 
death among the 3 groups within 12 months after TB treatment 
initiation. The multivariable model did suggest that being on 
ART and having a higher CD4 count at TB treatment initiation 
were associated with lower hazards for death.
Of the 833 patients with missing values, imputation was not 
performed for 138 cases due to missing facility level, TB dis-
ease site, or simultaneously missing BMI, ART status, and CD4 
count. Each imputed data set thus had 1953 patients. In the uni-
variate analysis, after imputing missing values, there was evi-
dence of a difference in the hazards of death among the 3 test 
groups (P = .030) (Table 3). However, after adjusting for other 
covariates, the effect of the test status on the hazard of death 
was not significant at the α = 0.05 level (P = .058). At the pair-
wise level, however, the hazard of death was 56% higher among 
those with no TB test results compared with positive tests (ad-
justed hazard ratio [aHR], 1.56; 95% CI, 1.08–2.26) (Table 3). 
The hazard of death was also higher among patients with neg-
ative tests compared with positive tests but was not significant 
at the α  =  0.05 level (aHR, 1.28; 95% CI, 0.91–1.64). Finally, 
the multivariable analysis also suggested that increasing age was 
associated with an increased hazard of death, while increasing 
CD4 count, being on ART at TB treatment initiation, and re-
ceiving care from a tertiary facility were associated with a de-
creased hazard of death.
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West Africa
East Africa
Central Africa
CCASAnet
• Senegal (n = 43)
• Côte d'lvoire (n = 68)
• México (n = 13)
• Honduras (n = 20)
• Peru (n = 233)
• Brazil (n = 47)
• République Démocratique
  du Congo (n = 76)
• Rwanda (n = 32)
• Burundi (n = 48)
• Uganda (n = 480)
• Tanzania (n = 136)
• Kenya (n = 895)
Figure 1. Patients included in the analysis by International epidemiology Databases to Evaluate AIDS region and country.
Table 1. Patient Characteristics Stratified by TB Bacteriologic Test Status
Characteristic Bacteriologic Test Status
 Total (n = 2091), No. (%)
Positive Test 
(n = 615), No. (%)
Negative Test 
(n = 907), No. (%)
No Test Result  
(n = 569), No.  
(%) P Valuea
Age, median (IQR), y 36 (30–43) 35 (30–42) 36 (30–43) 36 (29–44) .779
Female sex 910 (44) 266 (43) 385 (42) 259 (46) .505
BMI, median (IQR), mg/kg2 19 (17–21) 18 (17–21) 19 (17–21) 19 (17–22) .001
 Missing 374 (18) 86 (14) 89 (10) 199 (35)  
ART status at TB treatment initiation     .069
 On ART 1084 (52) 346 (56) 475 (52) 216 (38)  
 Not on ART 790 (38) 215 (35) 359 (40) 263 (46)  
 Missing 217 (10) 54 (9) 73 (8) 90 (16)  
CD4 count, cells/mm3     .612
 <100 716 (34) 204 (33) 309 (34) 203 (36)  
 100–200 391 (19) 114 (19) 174 (19) 103 (18)  
 201–350 306 (14) 85 (14) 148 (16) 73 (13)  
 351–500 161 (8) 44 (7) 73 (8) 44 (8)  
 >500 118 (6) 36 (6) 59 (7) 23 (4)  
 Missing 399 (19) 132 (21) 144 (16) 123 (21)  
TB disease siteb     <.001
 Pulmonary 1646 (79) 564 (92) 732 (81) 350 (62)  
 Miliary 18 (1) 0 (0) 13 (2) 5 (1) .011
 Extrapulmonary 422 (20) 49 (8) 172 (19) 201 (35)  
 Pleural 79 (22) 3 (10) 36 (23) 40 (20) <.001
 Lymphatic 73 (20) 20 (67) 26 (17) 27 (13) .149
 Bone and/or joint 12 (34) 1 (3) 5 (3) 6 (3) .129
 Abdominalc 34 (10) 3 (10) 18 (11) 13 (7) .027
 Pericardial 7 (2) 0 (0) 4 (3) 3 (2) .276
 Genitourinary 1 (<1) 1 (3) 0 (0) 0 (0) .566
 CNS and/or meningeal 21 (6) 1 (3) 13 (8) 7 (3) .042
 Laryngeal 1 (<1) 0 (0) 1 (1) 0 (0) 1.000
 Other 25 (7) 0 (0) 11 (7) 14 (7) <.001
 Not specified 23 (1) 2 (<1) 3 (<1) 18 (3) <.001
Abbreviations: ART, antriretroviral therapy; BMI, body mass index; CNS, central nervous system; IQR, interquartile range; TB, tuberculosis.
aP values comparing the 3 groups were calculated using analysis of variance F-test, chi-square test, Kruskal-Wallis test, and Fisher exact test.
bPercentages of extrapulmonary sites refer to the total extrapulmonary sites; each patient could have >1 extrapulmonary site.
cIncludes peritoneum, omentum, liver, spleen, and colon.
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Secondary Analysis
The propensity model for the log-odds of having any bacteri-
ologic test (positive or negative) vs no test result showed that 
CD4 count, BMI, TB disease site, facility level, and IeDEA 
region were associated with the probability of having a test re-
sult (Supplementary Table 6). The odds of having a test result 
among those with extrapulmonary TB, for example, were esti-
mated to be about 45% lower than the odds for those with pul-
monary TB (P  <  .0001) (Supplementary Table 7). The model 
in Supplementary Table 6 was used to calculate the propensity 
scores used to compute stabilized IPWs. The stabilized IPWs 
were used to adjust Cox models for the time to death condi-
tional on whether a bacteriologic diagnosis was observed. The 
pooled adjusted hazard ratio suggested that the hazard of death, 
within 12  months of initiating TB treatment, was about 19% 
lower among those with a bacteriologic test compared with 
those without a test but was not significant at the α = 0.05 level 
(aHR, 0.81; 95% CI, 0.61–1.07) (Supplementary Table 8).
DISCUSSION
PWH in our cohorts treated for TB in the absence of TB bacte-
riologic test results had a significantly higher adjusted hazard of 
death than those treated for TB with positive test results in the 
multiple imputation analysis. This association was not signifi-
cant in the complete case analysis, which included only 64% of 
the sample size in the multiple imputation analysis and whose 
coefficients were far more sensitive to adjustment. Unlike those 
with bacteriologically confirmed TB, it is plausible that those 
with no test results were a heterogenous group of individuals 
with TB and other life-threatening diseases (eg, opportun-
istic infections, cancers, chronic lung diseases) that may have 
Table 2. Patient Distribution by Site Characteristics, Stratified by TB Bacteriologic Test Status
Characteristic Bacteriologic Test Status
 
Total (n = 2091),  
No. (%)
Positive Test 
(n = 615), No. (%)
Negative Test 
(n = 907), No. (%)
No Test  
(n = 569), No. (%) P Valuea
IeDEA region     <.001
 CCASAnet 313 (15) 126 (21) 77 (8) 110 (19)  
 Central Africa 156 (8) 52 (8) 44 (5) 60 (11)  
 East Africa 1511 (72) 397 (64) 734 (81) 380 (67)  
 West Africa 111 (5) 40 (7) 52 (6) 19 (3)  
Setting     <.001
 Urban 537 (26) 198 (32) 151 (17) 188 (33)  
 Peri-urban 986 (47) 286 (46) 393 (43) 307 (54)  
 Rural 480 (23) 84 (14) 324 (36) 72 (13)  
 Missing 88 (4) 47 (8) 39 (4) 2 (<1)  
Facility level     <.001
 Secondary 234 (12) 96 (15) 56 (6) 82 (14)  
 Tertiary 1769 (88) 472 (77) 812 (90) 485 (85)  
 Missing 88 (4) 47 (8) 39 (4) 2 (<1)  
Specialized TB clinic/ward on site     <.001
 Yes, on site 1951 (93) 550 (89) 858 (95) 543 (95)  
 Yes, off site/by referral 20 (1) 3 (<1) 5 (<1) 12 (2)  
 Not available 32 (2) 15 (2) 5 (<1) 12 (2)  
 Missing 88 (4) 47 (8) 39 (4) 2 (<1)  
Physical proximity of HIV/TB services     <.001
 Same facility or same-day appointments 1440 (69) 341 (55) 709 (78) 390 (69)  
 Cross-referral between HIV and TB service points 401 (19) 158 (26) 84 (9) 159 (28)  
 Provision of TB and HIV services under the same 
roof 
114 (5) 52 (8) 44 (5) 18 (3)  
 None of these models 48 (2) 17 (3) 31 (3) 0 (0)  
Missing 88 (4) 47 (8) 39 (4) 2 (<1)  
Active screening for TB for all PWH at enrollment     <.001
 All, but only symptom screening 199 (10) 91 (15) 32 (4) 76 (13)  
 All, symptom screening plus additional diagnosticsb 1689 (81) 425 (69) 785 (86) 479 (84)  
 In case of clinical suspicion 115 (5) 52 (8) 51 (6) 12 (2)  
Missing 88 (4) 47 (8) 39 (4) 2 (<1)  
Abbreviations: CCASAnet, Caribbean, Central and South America; IeDEA, International epidemiology Databases to Evaluate AIDS; PWH, people with HIV; TB, tuberculosis.
aAnalysis of variance F-test, chi-square test, Kruskal-Wallis test, or Fisher exact test was performed for each variable as appropriate.
bAdditional testing examples include sputum AFB, sputum induction, gastric lavage, tissue biopsy, chest x-ray, gene x-pert, tuberculin skin testing.
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mimicked TB but advanced untreated while the patient received 
TB treatment, resulting in excess mortality. This, along with the 
12-month mortality outcome, suggests that not all patients who 
initiated TB treatment had TB disease and not all deaths were 
TB-attributable.
Consistent with the literature, being on ART and having 
higher CD4 count at TB treatment initiation were strongly 
protective against mortality in our study. This underscores the 
importance of early ART initiation and immune preservation 
on survival, regardless of TB bacteriologic testing in resource-
constrained settings. Advanced HIV immunosuppression is 
known to be a critical risk factor for TB-related mortality, and 
the scale-up of ART coverage has been associated with marked 
reductions in TB incidence and mortality [20, 21, 42, 43, 51–53].
We also found that PWH attending tertiary facilities had a 
lower adjusted hazard of death compared with those attending 
secondary facilities. It is possible that secondary facilities had less 
capacity to evaluate and manage TB or its alternative diagnoses 
compared with tertiary facilities [54]. However, there was not 
a significant difference in the adjusted hazard of death in those 
treated for TB with any test vs no test, which argues against the 
notion that bacteriologic testing is a marker of better-resourced 
sites and therefore reduced mortality. Facility-level mortality 
differences may also have been influenced by differences in the 
completeness of vital status ascertainment between higher- and 
lower-resourced facilities, the latter being potentially more sus-
ceptible to undocumented loss to follow-up or transfer events 
not captured in our data set [55]. Differences in vital status ascer-
tainment may also have accounted for regional differences in the 
hazards for death (ie, West Africa vs CCASAnet) in our study.
Notably, the increased mortality among PWH with no TB 
test results in our study was independent of patients’ TB disease 
site and CD4 count (Table 1). This reduces the possibility that 
extrapulmonary TB (which was more prevalent in those with no 
tests than positive tests) or advanced HIV disease were driving 
the increased mortality in the no test group. The potential influ-
ence of extrapulmonary TB on mortality in our study neverthe-
less remains an important consideration. Extrapulmonary TB 
is known to be more common in advanced HIV disease, cer-
tain extrapulmonary TB sites (eg, disseminated or meningitis) 
have been associated with especially high mortality in PWH, 
and extrapulmonary TB has been associated with delays in di-
agnosis [42, 44, 45, 56–59]. The diagnosis of extrapulmonary 
TB and extrapulmonary disease sites may be less accurate in 
patients without bacteriologically confirmed TB in our study. 
This accuracy may improve over time with the broader use of 
urinary LAM, which does not require sputum collection and is 
not site-specific.
The use of NAAT in only 3% of patients in our study is lower 
than expected in light of a 2012 global IeDEA site assessment 
that identified that Xpert MTB/RIF to be accessible at 63% of 
sites (in the clinic, at the same facility, and/or offsite) [4]. This 
gap between accessibility and utilization of Xpert MTB/RIF 
may be attributable to a variety of factors, including evolving 
country-specific policy during the study period, lack of pro-
vider knowledge about Xpert and WHO guidelines, cartridge 
stock-outs, interruptions in electricity, unreliable transport of 
specimens at sites with off-site Xpert availability, and high op-
erating costs in resource-limited settings. The low utilization 
of Xpert despite its increasing availability may also be a factor 
in the lack of increase in the proportion of notified pulmo-
nary TB cases that are bacteriologically confirmed in low- and 
middle-income countries according to the recent WHO Global 
Tuberculosis Report 2019 [6].
Finally, patients with negative tests had a 28% higher hazard 
of death than those with positive tests in the adjusted multiple 
imputation analysis, but the difference was not statistically sig-
nificant. Other studies have found that smear-negative TB is as-
sociated with increased mortality compared with smear-positive 
TB in PWH, which has been attributed to paucibacillary disease 
in advanced HIV, delay in diagnosis, and other opportunistic 
and noncommunicable diseases [15, 21–23, 60–67]. Similar 
findings have been shown with respect to TB culture, but such 
studies have not been performed for NAAT to our knowledge 
[68]. The lack of mortality difference in our study could thus be 
related to the combination of smear, culture, and NAAT used 
to define the groups. The positive test group may also have had 
higher-than-expected mortality due to more extensive TB dis-
ease (with higher bacterial burden) or inadequate treatment of 
drug-resistant TB [69].
Our study has strengths and limitations. The strengths in-
clude its large sample size from diverse regions and use of 
P = .017
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Figure 2. Cumulative incidence of survival after tuberculosis (TB) treatment initi-
ation, stratified by TB bacteriologic test status: red, positive test group; blue, nega-
tive test group; gray, no test result group.
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routine program data, likely reflecting typical care environ-
ments. The limitations include the use of multiple imputation if 
the variables used to impute missing values were not missing at 
random, although missing CD4 counts, for example, were often 
attributable to reagent stock-outs, suggesting that this variable 
was missing at random. Few patients had culture or NAAT, and 
none had LAM test results, which limits the generalizability of 
our study in current settings where these tests are used more 
commonly. Finally, the use of retrospective data limited our 
ability to understand the extent of clinicians’ efforts to diagnose 
TB and other diseases or the reasons why patients had negative 
or no TB test results (eg, clinical or laboratory system failures).
In conclusion, there was some evidence that PWH treated for 
TB with no TB bacteriologic test results were at higher risk of 
death than those treated for TB with positive bacteriologic tests. 
Every effort should be made to establish a bacteriologic diagnosis 
of TB before TB treatment initiation in resource-constrained 
settings. Research is needed to understand the causes of death 
in PWH treated for TB without bacteriologic testing.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Acknowledgments
We are grateful for the participation of the following IeDEA 
Collaborative sites: Brazil—INI-Fiocruz; Burundi—CPAMP-CHUK; 
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